C4 Therapeutics, Inc.

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

CEO Christopher Viehbacher has said consistently since he took the helm of Biogen in 2022 that the company will grow through both internal and external innovation, with an overarching goal of diversif

Among the presentations at the European Society for Medical Oncology meeting in Barcelona, Spain will be data for older immune checkpoint inhibitors from Merck & Co., Inc. , AstraZeneca PLC and Br

C4 Therapeutics is on a roll in finding partners to advance its protein degradation platform, signing a deal with Merck KGaA to develop two oncology assets. The collaboration will center on two pre